阿德福韦酯联合苦参素胶囊对慢性乙型肝炎患者HBV复制及T淋巴细胞亚群的影响

Effects of adefovir dipivoxil in combination with Marine Capsules on HBV replication and T lymphocyte subsets in patients with chronic hepatitis B

目的:探讨阿德福韦酯联合苦参素抗病毒治疗对HBeAg阳性慢性乙型肝炎患者病毒复制指标及T淋巴细胞亚群的影响.方法:将106例慢性乙型肝炎患者随机分为治疗组和对照组.治疗组60例,给予阿德福韦酯联合苦参素胶囊治疗;对照组46例,单用阿德福韦酯治疗;2组疗程均为48wk.结果:疗程结束后,组HBVDNA、HBeAg阴转率以及HBeAg/抗HBe转换率显著高于对照组,差异有统计学意义(71.67%vs32.61%;53.33%vs15.22%;45.00%vs13.04%,均P<0.05);治疗组CD4+以及CD4+/CD8+也较对照组明显升高,差异有统计学意义(38.61%±5.28%vs30.16%±5.11%;1.52%±0.32%vs0.73%±0.30%,均P<0.05).结论:阿德福韦酯与苦参素联合应用可显著提高疗效,并能显著改善慢性乙型肝炎患者外周血T淋巴细胞亚群状态.

AIM： To observe the effects of adefovir dipivoxil in combination with Marine Capsules on hepatitis B virus （HNV） replication and T lymphocyte subsets in patients with hepatitis B surface antigen （HbeAg）-positive chronic hepatitis B （CHB）. METHODS： One hundred and six patients with CHB were randomly divided into control group （n = 46） and treatment group （n = 60）. Patients in the control group received adefovir dipivoxil alone, while those in the treatment group received both adefovir dipivoxil and Marine Capsules. The period of treatment was 48 weeks. RESULTS： At the end of treatment, the negative conversion rates of HBV DNA and HBeAg and HBeAg/anti-HBe seroconversion rate were significantly higher in the treatment group than in the control group （71.67% vs 32.61%, 53.33% vs 15.22%, and 45.00% vs 13.04%, respectively; all P 〈 0. 05）. The percentages of CD4^＋ and CD4^＋/ CD8^＋ T lymphocytes were significantly higher in the treatment group than in the control group （38.61% ± 5.28% vs 30.16% ± 5.11%, and 1.52% ± 0.32% vs 0.73%± 0.30%, respectively; both P 〈 0.05）. CONCLUSION： Adefovir dipivoxil in combination with Marine Capsules can significantly improve efficacy and increase the percentages of CD4^＋ and CD4^＋/CD8^＋ T lymphocytes in patients with CHB.